Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaMarina Konopleva, Hagop Kantarjian, Teresa J. Melink et al.|Haematologica|2015Cited by 121
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trialElias Jabbour, Hagop Kantarjian, Nicola Gökbuget et al.|Leukemia Research|2019Cited by 52
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemiaNaval Daver, Srđan Verstovšek, Linghsa Zhou et al.|Leukemia Research|2014Cited by 30
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or AsciminibElias Jabbour, H. Kantarjian, Vivian G. Oehler et al.|JAMA Oncology|2024Cited by 26
Management of Adult Acute Lymphoblastic LeukemiaHagop M. Kantarjian, Elias Jabbour, Ibrahim Aldoss|JAMA Oncology|2025Cited by 15